Core Laboratories (CLB) Liabilities and Shareholders Equity (2022 - 2026)

Core Laboratories' Liabilities and Shareholders Equity history runs 5 years deep, the most recent figure standing at $586.8 million for Q2 2026.

• In Q2 2026, Liabilities and Shareholders Equity fell 1.69% year-over-year to $586.8 million; the TTM figure through Jun 2026 stood at $2.3 billion (down 0.79% YoY), while the FY2025 annual figure was $584.0 million, changed 0.19% from the prior year.
• Liabilities and Shareholders Equity for Q2 2026 stood at $586.8 million, roughly flat from $587.7 million in the prior quarter.
• The five-year high for Liabilities and Shareholders Equity was $601.8 million in Q2 2023, with the low at $570.2 million in Q3 2022.
• The 5-year median for Liabilities and Shareholders Equity is $587.7 million (2026), against an average of $589.1 million.
• The sharpest annual moves came in 2023 and 2025: Liabilities and Shareholders Equity rose 4.21% in 2023, then dropped 1.93% in 2025.
• Core Laboratories' Liabilities and Shareholders Equity stood at $578.4 million in 2022, then increased by 1.39% to $586.4 million in 2023, then slipped by 0.22% to $585.1 million in 2024, then slipped by 0.19% to $584.0 million in 2025, then increased by 0.47% to $586.8 million in 2026.
• Business Quant data shows CLB's Liabilities and Shareholders Equity at $586.8 million in Q2 2026, $587.7 million in Q1 2026, and $584.0 million in Q4 2025.